UPLOAD Filing
Acurx Pharmaceuticals, Inc.
Date: May 27, 2025 · CIK: 0001736243 · Accession: 0000000000-25-005562
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287478
Letter
Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed May 21, 2025 File No. 333-287478 Dear David Luci:
May 27, 2025
David Luci Chief Executive Officer Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, NY 10305
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ivan Blumenthal, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 27, 2025 David Luci Chief Executive Officer Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, NY 10305 Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed May 21, 2025 File No. 333-287478 Dear David Luci: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ivan Blumenthal, Esq. </TEXT> </DOCUMENT>